SCHEMBL4908596

SCHEMBL4908596

CCOc1ccc2nc(SCCNS(=O)(=O)c3ccc(C)c(C(=O)OC)c3)sc2c1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.70
LMNA P02545 5/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
ALOX5 P09917 2/20 0.57
HPGD P15428 3/20 0.51
ALDH1A1 P00352 3/20 0.51
HTT P42858 1/20 0.51
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
GAA P10253 1/20 0.49
PPARA Q07869 5/20 0.48
POLB P06746 1/20 0.48
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4903629 0.93 MAPT (0.73) MAPTLMNASMN1; SMN2ALOX5HPGD
SCHEMBL4906185 0.92 MAPT (0.68) MAPTLMNASMN1; SMN2ALOX5HPGD
SCHEMBL4905936 0.86 SMN1; SMN2 (0.54) MAPTLMNASMN1; SMN2ALOX5HPGD
SCHEMBL4902974 0.86 MAPT (0.72) MAPTLMNASMN1; SMN2ALOX5HPGD
SCHEMBL4905743 0.82 ALOX5 (0.54) MAPTLMNASMN1; SMN2ALOX5HPGD
SCHEMBL4908602 0.81 PPARA (0.48) MAPTLMNASMN1; SMN2ALOX5HPGD
SCHEMBL5930594 0.78 MAPT (0.63) MAPTLMNASMN1; SMN2ALOX5HPGD
SCHEMBL4906166 0.78 MAPT (0.55) MAPTLMNASMN1; SMN2ALOX5HPGD
SCHEMBL4904118 0.77 SMN1; SMN2 (0.52) MAPTLMNASMN1; SMN2ALOX5HPGD
SCHEMBL4906196 0.74 PPARA (0.47) MAPTLMNASMN1; SMN2ALOX5HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds HAMANAKA ERNEST S 2006-10-12 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARA, PPARG, PPARD MAPT 1858/4885LMNA 317/4885SMN1; SMN2 3271/4885
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD MAPT 1786/4885LMNA 319/4885SMN1; SMN2 3404/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD MAPT 1786/4885LMNA 319/4885SMN1; SMN2 3404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.